Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference being held from February 7-8, 2024 in New York.

Details of the event are as follows:

Date: Thursday, February 8, 2024

Time: 3:00 p.m. ET

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.37
-4.63 (-1.82%)
AAPL  270.28
+1.23 (0.46%)
AMD  251.81
-7.84 (-3.02%)
BAC  53.38
-0.18 (-0.34%)
GOOG  277.56
-6.56 (-2.31%)
META  628.64
-9.07 (-1.42%)
MSFT  512.82
-4.21 (-0.81%)
NVDA  199.06
-7.81 (-3.78%)
ORCL  247.36
-10.49 (-4.07%)
TSLA  446.08
-22.29 (-4.76%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.